Start your CoreAge Rx note with the selected treatment and the selected plan length. The product pages advertise compounded semaglutide from $99 per month and compounded tirzepatide from $149. Those starting figures are useful for opening a conversation, but they do not establish the charge for every plan or the treatment a clinician will prescribe.
Ask about the order you are actually making
The help center describes one-, three-, six- and twelve-month plans. It also distinguishes one-time purchases from optional subscriptions. A longer plan is therefore not automatically the same thing as agreeing to recurring billing. Before paying, ask which choice is selected and save the total amount, supplied term and any renewal instructions together.
The published terms say pricing does not rise with dose and includes medicine, clinical review and shipping. Treat those as the provider's stated offer. We have not completed checkout as a patient or independently tested fulfillment. Confirm the written order matches the offer you expect.
Leave the medicine question with the clinician
A compounded medicine is not FDA-approved. Ask why that preparation is appropriate for your needs and which pharmacy will dispense it. You should also know whom to contact if the product or instructions need clarification after delivery.
Before you close the page
The help center says sales become final once the prescription is approved and sent to the pharmacy. Stopping a future subscription and obtaining a refund for an existing order are different requests. Read the stage-dependent terms before submitting an order. Our #1 position is promotional placement, not a finding that CoreAge provides better medical outcomes.
Sources for this note
Checked October 5, 2026. Provider sources describe advertised offers; they do not independently establish quality of care.
- CoreAge Rx — official treatment pagesProvider offer
- CoreAge Rx — tirzepatide offerProvider offer
- CoreAge Rx Help Center — Pricing & PlansProvider billing terms
- FDA — compounding questions and answersRegulator guidance